Risk of Hepatitis B Reactivation Among ALL Patients With Occult Hepatitis B Infection
JCO Global Oncology · 2026
DOI: 10.1200/go-25-00262 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JCO Global Oncology, 2026. Verfasst von Hasmukh Jain und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tata Memorial Centre, Mumbai, India. Hauptthemen laut MEDLINE: Hepatitis B, Virus Activation, Hepatitis B virus, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Anticancer therapy increases the risk of hepatitis B virus (HBV) reactivation in patients with occult hepatitis B infection (OHBI), particularly in those who receive rituximab or stem-cell transplantation. However, the exact risk of HBV reactivation in patients with ALL/lymphoblastic lymphoma (LBL) receiving prolonged, intensive myelosuppressive chemotherapy is not known and thus the role of antiviral prophylaxis is not clearly established. PATIENTS AND METHODS This prospective observational study was conducted at a single tertiary cancer center in India (October 2017 to August 2021). Patients age 15 years and older with ALL/LBL were screened for OHBI and enrolled. Liver function tests and HBV DNA levels were monitored at baseline, during treatment, and throughout follow-up phase. During episodes of hepatitis, extended serology panel was performed. The primary end point was the incidence of HBV reactivation. RESULTS OHBI was identified in 30.4% (172/566) of patients treated at our center during the study period. In the prospective cohort, 65 patients with ALL/LBL and OHBI, treated on a pediatric-inspired protocol, were enrolled. HBV reactivation occurred in six patients (9.2%; 95% CI, 4.3 to 18.7), none of whom developed HBV-related hepatitis. Seventeen patients experienced at least one episode of grade ≥3 hepatitis, with a median AST of 401 U/L (range, 192-3,490) and ALT of 430 U/L (range, 255-1,950). Hepatitis led to chemotherapy delays in five patients, with a median delay of 15.5 days (range, 7-39). CONCLUSION Our findings indicate a moderate to high risk of HBV reactivation in ALL/LBL patients with OHBI treated with pediatric-inspired protocols, particularly during maintenance, supporting prophylactic antiviral therapy as standard practice in regions with high or intermediate HBV endemicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medical Oncology, Tata Memorial Centre, Mumbai, India.
- Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, India.
- Clinical Research Secretariat, Tata Memorial Centre, Mumbai, India.
- Department of Medical Oncology, SMBT Cancer Institute, Nashik, India.
- Department of Microbiology, Tata Memorial Centre, Mumbai, India.
- Department of Medical Gastroenterology, Tata Memorial Centre, Mumbai, India.
ORCID-Profile: Hasmukh Jain, Devanshee Shah, Thomas Eipe, Bhausaheb Bagal, Lingaraj Nayak, Alok Shetty, Anupa John, Manju Sengar
Zitieren
APA
Jain, H., Sharma, N., Shah, D., Eipe, T., Ghandade, N., Thorat, J., Bagal, B., Nayak, L., Shetty, A., John, A., Biswas, S. K., Salunkhe, G., Sundaram, S., Patil, P. S., & Sengar, M. (2026). Risk of Hepatitis B Reactivation Among ALL Patients With Occult Hepatitis B Infection. JCO Global Oncology. https://doi.org/10.1200/go-25-00262
Vancouver
Jain H, Sharma N, Shah D, Eipe T, Ghandade N, Thorat J, et al. Risk of Hepatitis B Reactivation Among ALL Patients With Occult Hepatitis B Infection. JCO Global Oncology. 2026. doi:10.1200/go-25-00262
BibTeX
@article{Jain2026,
author = {Jain, Hasmukh and Sharma, Neha and Shah, Devanshee and Eipe, Thomas and Ghandade, Netra and Thorat, Jayashree and Bagal, Bhausaheb and Nayak, Lingaraj and Shetty, Alok and John, Anupa and Biswas, Sanjay K and Salunkhe, Gaurav and Sundaram, Sridhar and Patil, Prachi S and Sengar, Manju},
title = {Risk of Hepatitis B Reactivation Among ALL Patients With Occult Hepatitis B Infection},
journal = {JCO Global Oncology},
year = {2026},
doi = {10.1200/go-25-00262}
}
EUVIMED